Kim Discusses the Development of LP-300 Plus Chemotherapy in Advanced Lung Cancer

In Partnership With:

Partner | Cancer Centers | <b>City of Hope</b>

Dr Kim discusses the evaluation of LP-300 for the treatment of patients with advanced lung adenocarcinoma, the rationale for exploring this agent in combination with chemotherapy, and the ongoing HARMONIC trial investigating the combination of LP-300 plus carboplatin and pemetrexed.

Welcome to OncLive On Air®! I’m your host today, Chris Ryan.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Lantern Pharma, we had the pleasure of speaking with Edward S. Kim, MD, MBA, about the evaluation of LP-300 for the treatment of patients with advanced lung adenocarcinoma. Kim is the physician-in-chief of City of Hope Orange County and the vice physician-in-chief of City of Hope National Medical Center in Duarte, California.

In our exclusive interview, Kim discussed the background of the cysteine-modifying agent LP-300, the rationale for exploring its use in combination with chemotherapy in patients who are never smokers with advanced lung adenocarcinoma, and the ongoing phase 2 HARMONIC trial (NCT05456256) investigating the combination of LP-300 plus carboplatin and pemetrexed (Alimta).

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Lantern Pharma. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.